Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk.
DNA methylation
pancreatic cancer
risk factors
single‐nucleotide polymorphism
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
revised:
13
03
2024
received:
17
04
2023
accepted:
20
03
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
Correlated regions of systemic interindividual variation (CoRSIV) represent a small proportion of the human genome showing DNA methylation patterns that are the same in all human tissues, are different among individuals, and are partially regulated by genetic variants in cis. In this study we aimed at investigating single-nucleotide polymorphisms (SNPs) within CoRSIVs and their involvement with pancreatic ductal adenocarcinoma (PDAC) risk. We analyzed 29,099 CoRSIV-SNPs and 133,615 CoRSIV-mQTLs in 14,394 cases and 247,022 controls of European and Asian descent. We observed that the A allele of the rs2976395 SNP was associated with increased PDAC risk in Europeans (p = 2.81 × 10
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione Arpa
Organisme : Intramural funding of German Cancer Research Center (DKFZ)
Organisme : Fondazione Tizzi
Organisme : Ministero della Salute
ID : FIMP_ CUP J37G22000230001
Organisme : Ministero della Salute
ID : Ricerca Corrente 2022-2024
Organisme : Associazione Italiana per la Ricerca sul Cancro, AIRC IG
ID : 2021-26201
Organisme : Associazione Italiana per la Ricerca sul Cancro, AIRC IG
ID : 26343
Organisme : Ministry of Health Czech Republic
ID : NU21-03-00499
Organisme : 5x1000 voluntary contribution
Informations de copyright
© 2024 UICC.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7‐33.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209‐249.
Singhi AD, Koay EJ, Chari ST, Maitra A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019;156:2024‐2040.
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493‐502.
Lu Y, Gentiluomo M, Lorenzo‐Bermejo J, et al. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. J Med Genet. 2020;57(12):820‐828.
Galeotti AA, Gentiluomo M, Rizzato C, et al. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. J Med Genet. 2020;58(6):369‐377. doi:10.1136/jmedgenet‐2020‐106961
Campa D, Gentiluomo M, Obazee O, et al. Genome‐wide association study identifies an early onset pancreatic cancer risk locus. Int J Cancer. 2020;147(8):2065‐2074. doi:10.1002/ijc.33004
Amundadottir L, Kraft P, Stolzenberg‐Solomon RZ, et al. Genome‐wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41:986‐990.
Wolpin BM, Rizzato C, Kraft P, et al. Genome‐wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet. 2014;46:994‐1000.
Petersen GM, Amundadottir L, Fuchs CS, et al. A genome‐wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010;42:224‐228.
Childs EJ, Mocci E, Campa D, et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet. 2015;47:911‐916.
Lin Y, Nakatochi M, Hosono Y, et al. Genome‐wide association meta‐analysis identifies GP2 gene risk variants for pancreatic cancer. Nat Commun. 2020;11:3175.
Klein AP, Wolpin BM, Risch HA, et al. Genome‐wide meta‐analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun. 2018;9:556.
Campa D, Rizzato C, Stolzenberg‐Solomon R, et al. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Int J Cancer. 2015;137:2175‐2183.
Giaccherini M, Farinella R, Gentiluomo M, et al. Association between a polymorphic variant in the CDKN2B‐AS1/ANRIL gene and pancreatic cancer risk. Int J Cancer. 2023;153(2):373‐379.
Gentiluomo M, Peduzzi G, Lu Y, Campa D, Canzian F. Genetic polymorphisms in inflammatory genes and pancreatic cancer risk: a two‐phase study on more than 14 000 individuals. Mutagenesis. 2019;34:395‐401.
Rizzato C, Campa D, Giese N, Werner J, et al. Pancreatic cancer susceptibility loci and their role in survival. PLoS One. 2011;6:e27921.
Rizzato C, Campa D, Pezzilli R, Soucek P, et al. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncol Rep. 2013;29:1637‐1644.
Campa D, Pastore M, Gentiluomo M, et al. Functional single nucleotide polymorphisms within the cyclin‐dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget. 2016;7:57011‐57020.
Campa D, Matarazzi M, Greenhalf W, et al. Genetic determinants of telomere length and risk of pancreatic cancer: a PANDoRA study. Int J Cancer. 2019;144:1275‐1283.
Gentiluomo M, Canzian F, Nicolini A, Gemignani F, Landi S, Campa D. Germline genetic variability in pancreatic cancer risk and prognosis. Semin Cancer Biol. 2022;79:105‐131.
Lu Y, Corradi C, Gentiluomo M, et al. Association of genetic variants affecting microRNAs and pancreatic cancer risk. Front Genet. 2021;12:1‐11.
Corradi C, Gentiluomo M, Gajdán L, et al. Genome‐wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Int J Cancer. 2021;148:2779‐2788.
Pistoni L, Gentiluomo M, Lu Y, et al. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Carcinogenesis. 2021;42:1037‐1045.
Natale F, Vivo M, Falco G, Angrisano T. Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis. Clin Epigenetics. 2019;11:132.
Bararia A, Dey S, Gulati S, et al. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions. Hepatobiliary Pancreat Dis Int. 2020;19:205‐217.
Silverman BR, Shi J. Alterations of epigenetic regulators in pancreatic cancer and their clinical implications. Int J Mol Sci. 2016;17:2138.
Tang B, Li Y, Qi G, et al. Clinicopathological significance of CDKN2A promoter hypermethylation frequency with pancreatic cancer. Sci Rep. 2015;5:13563.
Gunasekara CJ, Scott CA, Laritsky E, et al. A genomic atlas of systemic interindividual epigenetic variation in humans. Genome Biol. 2019;20:105.
Gunasekara CJ, MacKay H, Scott CA, et al. Systemic interindividual epigenetic variation in humans is associated with transposable elements and under strong genetic control. Genome Biol. 2023;24:2.
Campa D, Rizzato C, Capurso G, Giese N, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis. 2013;45:95‐99.
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta‐analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153‐160.
Gong J, Wan H, Mei S, et al. Pancan‐meQTL: a database to systematically evaluate the effects of genetic variants on methylation in human cancer. Nucleic Acids Res. 2019;47:D1066‐D1072.
Zheng Z, Huang D, Wang J, et al. QTLbase: an integrative resource for quantitative trait loci across multiple human molecular phenotypes. Nucleic Acids Res. 2020;48:D983‐D991.
Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection in regression, with application to genetic fine mapping. J R Stat Soc Series B Stat Methodol. 2020;82:1273‐1300.
Schork AJ, Thompson WK, Pham P, et al. All SNPs are not created equal: genome‐wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genet. 2013;9:e1003449.
Walsh N, Zhang H, Hyland PL, et al. Agnostic pathway/gene set analysis of genome‐wide association data identifies associations for pancreatic cancer. J Natl Cancer Inst. 2018;111(6):557‐567. doi:10.1093/jnci/djy155
Marra E, Uva P, Viti V, et al. Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer. 2010;10:129.
Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti‐PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA. 2001;98:2658‐2663.
Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res. 2010;16:3533‐3538.
Saeki N, Ono H, Yanagihara K, et al. rs2294008T, a risk allele for gastric and gallbladder cancers, suppresses the PSCA promoter by recruiting the transcription factor YY1. Genes Cells. 2015;20:382‐391.
Wang S, Tang J, Wang M, Yuan L, Zhang Z. Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. Carcinogenesis. 2010;31:621‐624.
Yang J, Li W, Zhang Z, et al. PSCArs2294008 T polymorphism increases the risk of bladder cancer in Bai, Dai, and Han ethnicity in China and a potential mechanism. Genes Genomics. 2018;40:531‐541.
Zhang W, Liang P, Wang W, et al. The influence of PSCA gene variation on its expression and gastric adenocarcinoma susceptibility in the northwest Chinese population. Int J Mol Sci. 2015;16:11648‐11658.
Fu Y‐P, Kohaar I, Rothman N, et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci USA. 2012;109:4974‐4979.
Májský A, Kyselová V. Prostate stem cell antigen (PSCA) and risk of bladder cancer: linking genotypes to functional mechanisms. Genome Biol. 2011;12:P15.
Xu L‐P, Qiu H‐B, Yuan S‐Q, Chen Y‐M, Zhou Z‐W, Chen Y‐B. Downregulation of PSCA promotes gastric cancer proliferation and is related to poor prognosis. J Cancer. 2020;11:2708‐2715.
Han KR, Seligson DB, Liu X, et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol. 2004;171:1117‐1121.
Link T, Kuithan F, Ehninger A, et al. Exploratory investigation of PSCA‐protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression. Oncotarget. 2017;8:54592‐54603.
Reiter RE, Sato I, Thomas G, et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer. 2000;27:95‐103.
Liu JZ, Van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979‐986.
Vujkovic M, Keaton JM, Lynch JA, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi‐ancestry meta‐analysis. Nat Genet. 2020;52:680‐691.
Lauc G, Essafi A, Huffman JE, et al. Genomics meets glycomics—the first GWAS study of human N‐glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet. 2010;6:1‐14.
Ley SH, Hegele RA, Connelly PW, et al. Assessing the association of the HNF1A G319S variant with C‐reactive protein in Aboriginal Canadians: a population‐based epidemiological study. Cardiovasc Diabetol. 2010;9:39.